

Ref: MHL/Sec&Legal/2024-25/90

February 04, 2025

To,  
**BSE Limited**  
Scrip Code: 542650

**National Stock Exchange of India Ltd.**  
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on Tuesday, February 04, 2025

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), this is to inform that the Board of Directors of the Company at its meeting held on Tuesday, February 04, 2025, has inter-alia, approved the following matters:

## 1. Financial results

Unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended December 31, 2024.

The unaudited standalone and consolidated financial results of the Company as approved by the Board of Directors together with the limited review report thereon for the quarter and nine months ended December 31, 2024, are enclosed herewith.

The financial results are also being made available on the Company's website at [www.metropolisindia.com](http://www.metropolisindia.com)

## 2. Change in Chief Financial Officer

Appointment of Mr. Sameer Patel as Chief Financial Officer and Key Managerial Personnel of the Company effective from February 10, 2025. This appointment will relieve Mr. Aditya Shinde from the additional role of Interim Chief Financial Officer and Key Managerial Personnel of the Company effective from the close business hours of February 09, 2025. Mr. Aditya Shinde will continue to serve as Finance Controller.

Further, in terms of Regulation 30(5) of the Listing Regulations, Mr. Sameer Patel is authorized by the Board, along with the existing authorized persons, for the purpose of determining materiality of an event or information and making disclosure of the same to the stock exchanges. His contact details are as follows:

Contact Details	Add: 4 <sup>th</sup> Floor, East Wing, Plot-254 B, Nirlon House, Dr. Annie Besant Road, Worli, Mumbai - 400030, Maharashtra, India. E-mail Id: <a href="mailto:investor.relations@metropolisindia.com">investor.relations@metropolisindia.com</a> Mobile: +91 8422801801
-----------------	--

## 3. Change in Senior Management Personnel

- Approved the change in designation of Mr. Alangadan Kannan from 'Chief Operating Officer' to 'Chief Business Officer – Region 1' effective from March 01, 2025.
- Approved the elevation of Mr. Glen Menezes from 'Head – Market Operations' to 'National Head – Customer Success' effective from March 01, 2025.



The details as required under the Listing Regulations are provided in '**Annexure A**' to this intimation.

The meeting of the Board of Directors commenced at 02:30 p.m. (IST) and concluded at 05:00 p.m. (IST).

You are requested to take the above information on record.

Thanking you,  
Yours faithfully,

For **Metropolis Healthcare Limited**

Kamlesh C Kulkarni  
Head – Legal & Secretarial

**Encl:** A/a



**Limited Review Report on unaudited standalone financial results of Metropolis Healthcare Limited for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****To the Board of Directors of Metropolis Healthcare Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Metropolis Healthcare Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

**Rajesh Mehra**

Partner

Mumbai

04 February 2025

Membership No.: 103145

UDIN:25103145BMOVRY4906

**Metropolis Healthcare Limited**

Registered and Corporate Office: 4th Floor, East Wing, Plot 254 B, Nirlon House, Dr. Annie Besant Road, Worli, Mumbai - 400030, Maharashtra, India

CIN: L73100MH2000PLC192798

Contact No.: 8422 801 801

Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070, Maharashtra, India

**Statement of Standalone Financial Results for the quarter and nine months ended 31 December 2024**

Sr. No.	Particulars	Quarter ended			Nine Months ended		(Rs. in Lakhs)
		31 December 2024 (Unaudited)	30 September 2024 (Unaudited)	31 December 2023 (Unaudited)	31 December 2024 (Unaudited)	31 December 2023 (Unaudited)	31 March 2024 (Audited)
		<b>1 Income</b>					
a) Revenue from operations	29,688.08	32,157.17	26,940.87	90,459.03	81,115.86	1,10,342.54	
b) Other income	303.23	359.20	518.85	945.08	997.78	1,199.67	
<b>Total Income</b>	<b>29,991.31</b>	<b>32,516.37</b>	<b>27,459.72</b>	<b>91,404.11</b>	<b>82,113.64</b>	<b>1,11,542.21</b>	
<b>2 Expenses</b>							
a) Cost of materials consumed	5,862.64	6,356.43	5,212.61	18,035.51	16,121.22	22,047.85	
b) Laboratory testing charges	220.46	285.95	202.40	745.60	701.35	993.14	
c) Employee benefits expense	6,972.12	6,947.82	6,296.45	20,328.73	18,546.75	24,659.70	
d) Finance costs	448.71	473.43	524.37	1,383.40	1,668.85	2,233.60	
e) Depreciation and amortisation expense	2,684.63	2,601.04	2,413.89	7,761.37	6,549.53	9,073.28	
f) Other expenses	10,122.79	10,365.13	9,346.87	29,810.71	27,290.48	36,793.73	
<b>Total Expenses</b>	<b>26,311.35</b>	<b>27,029.80</b>	<b>23,996.59</b>	<b>78,065.32</b>	<b>70,878.18</b>	<b>95,801.30</b>	
<b>3 Profit before tax (1) - (2)</b>	<b>3,679.96</b>	<b>5,486.57</b>	<b>3,463.13</b>	<b>13,338.79</b>	<b>11,235.46</b>	<b>15,740.91</b>	
<b>4 Tax expenses</b>							
Current tax :							
-for the year:	943.14	1,378.15	860.20	3,406.44	3,110.59	4,413.79	
-tax adjusted for earlier years:	1.28	(64.46)	(6.09)	(63.18)	(6.09)	(6.09)	
Deferred tax (credit)	(4.85)	(53.32)	(60.71)	(99.01)	(279.99)	(255.77)	
<b>Total tax expenses</b>	<b>939.57</b>	<b>1,260.37</b>	<b>793.40</b>	<b>3,244.25</b>	<b>2,824.51</b>	<b>4,151.93</b>	
<b>5 Profit for the period/year (3) -(4)</b>	<b>2,740.39</b>	<b>4,226.20</b>	<b>2,669.73</b>	<b>10,094.54</b>	<b>8,410.95</b>	<b>11,588.98</b>	
<b>6 Other comprehensive income</b>							
Items that will not be reclassified subsequently to profit and loss (net of tax)	(72.06)	(144.11)	(72.20)	(257.41)	(216.62)	(164.96)	
Items that will be subsequently reclassified to profit and loss (net of tax)	-	-	-	-	-	-	
<b>Other comprehensive income for the period /year (net of tax)</b>	<b>(72.06)</b>	<b>(144.11)</b>	<b>(72.20)</b>	<b>(257.41)</b>	<b>(216.62)</b>	<b>(164.96)</b>	
<b>7 Total comprehensive income (5) + (6)</b>	<b>2,668.33</b>	<b>4,082.09</b>	<b>2,597.53</b>	<b>9,837.13</b>	<b>8,194.33</b>	<b>11,424.02</b>	
<b>8 Paid-up equity share capital (face value - Rs. 2 per share)</b>	<b>1,025.35</b>	<b>1,024.83</b>	<b>1,024.45</b>	<b>1,025.35</b>	<b>1,024.45</b>	<b>1,024.54</b>	
<b>9 Other equity</b>	-	-	-	-	-	1,02,094.18	
<b>10 Earnings per share (Face value of Rs.2 each) basic- (Rs.)*</b>	<b>5.35</b>	<b>8.24</b>	<b>5.21</b>	<b>19.70</b>	<b>16.42</b>	<b>22.63</b>	
<b>Earnings per share (Face value of Rs.2 each) diluted - (Rs.)*</b>	<b>5.32</b>	<b>8.21</b>	<b>5.19</b>	<b>19.59</b>	<b>16.36</b>	<b>22.55</b>	

(\*not annualised for the quarters)

See accompanying notes to the unaudited standalone financial results






**NOTES:**

- 1 The standalone financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
- 2 The standalone financial results of the Company have been reviewed by the Audit Committee at their meeting held on 04 February 2025 and thereafter approved by the Board of Directors at their meeting held on 04 February 2025. The Statutory Auditors have issued an unmodified review opinion on the unaudited standalone financial results for the quarter and nine-months period ended 31 December 2024
- 3 Disclosure of segment –wise information is not applicable, as pathology services is the Company's only business segment.
- 4 In the month of May ,June and Nov 2024, the Nomination and Remuneration Committee of the Company approved grant of 65,700, 58,000 and 22,500 Restricted Stock Units (RSU) respectively, pursuant to the Metropolis – Restrictive Stock Unit Plan – 2020 to eligible employees of the Company. This is in addition to the RSU's approved under Restrictive Stock Unit Plan – 2020 to eligible employees of the Company / subsidiaries in the earlier years.
- 5 On 09 December 2024, the Board of Directors of the Company approved acquisition of 100% stake in Core Diagnostics Private Limited, India, from its existing shareholder, Core Diagnostics (Mauritius) Private Limited for a total purchase consideration of Rs. 24,683 lakhs. Following the board approval, the Company has signed share purchase agreement on 09 December 2024. However, pending closure of the conditions precedent, no impact has been given in these results.
- 6 The standalone financial results of the Company are available for investors at [www.metropolisindia.com](http://www.metropolisindia.com), [www.nscindia.com](http://www.nscindia.com) and [www.bseindia.com](http://www.bseindia.com).

For Metropolis Healthcare Limited

  
Ameera Shah  
Chairperson and Wholetime Director  
DIN: 00208095  
Place: Mumbai  
Date: 04 February 2025



## Limited Review Report on unaudited consolidated financial results of Metropolis Healthcare Limited for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

### To the Board of Directors of Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Metropolis Healthcare Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement:
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The Statement includes the interim financial information of 10 (Ten) Subsidiaries which have not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 3,169.37 lakhs and Rs. 9,080.90 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 231.19 lakhs and Rs. 982.47 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 142.77 lakhs and Rs. 1,114.23 lakhs, for the quarter ended 31 December 2024 and for the period from 01 April 2024 to 31 December 2024 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.



Registered Office:

B S R & Co. LLP

**Limited Review Report (Continued)**  
**Metropolis Healthcare Limited**

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022



**Rajesh Mehra**

*Partner*

Membership No.: 103145

UDIN:25103145BMOVRZ6988

Mumbai

04 February 2025

**Limited Review Report (Continued)**  
**Metropolis Healthcare Limited**

**Annexure I**

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Metropolis Healthcare Limited	Parent
2	Ekopath Metropolis Lab Services Private Limited	Subsidiary
3	Amins Pathology Laboratory Private Limited	Wholly subsidiary owned
4	Metropolis Histoxpert Digital Services Private Limited	Wholly subsidiary owned
5	Centralab Healthcare Services Private Limited	Wholly subsidiary owned
6	Metropolis Foundation	Wholly subsidiary owned
7	Metropolis Healthcare (Mauritius) Limited	Wholly subsidiary owned
8	Metropolis Star Lab Kenya Limited	Wholly subsidiary owned
9	Metropolis Healthcare Ghana Limited	Wholly subsidiary owned
10	Metropolis Bramser Lab Services (Mtius) Limited	Wholly subsidiary owned
11	Metropolis Healthcare (Tanzania) Limited	Wholly subsidiary owned
12	Metropolis Healthcare Lanka Private Limited	Wholly subsidiary owned
13	Metropolis Healthcare Uganda Limited	Wholly subsidiary owned
14	Metropolis Clinical Pathology Private Limited	Wholly subsidiary owned





**Metropolis Healthcare Limited**

Registered and Corporate Office: 4th Floor, East Wing, Plot 254 B, Nirlon House, Dr Annie Besant Road, Worli, Mumbai - 400030, Maharashtra, India

CIN: L73100MH2000PLC192798

Contact No.: 8422 801 801

Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohnoor Mall, Vidyavihar (West), Mumbai - 400070, Maharashtra, India

**METROPOLIS**

**Statement of Consolidated Financial Results for the quarter and nine months ended 31 December 2024**

Sr. No.	Particulars	(Rs. in Lakhs)					
		Quarter ended			Nine months ended		Year ended
		31 December 2024 (Unaudited)	30 September 2024 (Unaudited)	31 December 2023 (Unaudited)	31 December 2024 (Unaudited)	31 December 2023 (Unaudited)	31 March 2024 (Audited)
<b>1</b>	<b>Income</b>						
	a) Revenue from operations	32,276.74	34,978.88	29,111.71	98,591.13	87,670.88	1,20,770.88
	b) Other income	255.56	312.90	230.61	814.24	657.76	911.70
	<b>Total Income</b>	<b>32,532.30</b>	<b>35,291.78</b>	<b>29,342.32</b>	<b>99,405.37</b>	<b>88,328.64</b>	<b>1,21,682.58</b>
<b>2</b>	<b>Expenses</b>						
	a) Cost of materials consumed	6,454.60	6,945.51	5,724.90	19,715.24	17,547.43	24,256.89
	b) Laboratory testing charges	239.90	308.15	209.00	814.38	732.03	1,357.68
	c) Employee benefits expense	8,143.00	7,843.86	6,950.54	23,155.56	20,431.80	27,578.35
	d) Finance costs	453.26	479.18	530.74	1,397.66	1,696.64	2,253.58
	e) Depreciation and amortisation expense	2,769.66	2,681.81	2,499.06	8,005.64	6,805.05	9,446.78
	f) Other expenses	10,238.32	10,893.70	9,742.59	30,836.04	28,700.00	39,320.41
	<b>Total Expenses</b>	<b>28,298.74</b>	<b>29,152.21</b>	<b>25,656.83</b>	<b>83,924.52</b>	<b>75,912.95</b>	<b>1,04,213.69</b>
<b>3</b>	<b>Profit before tax (1) - (2)</b>	<b>4,233.56</b>	<b>6,139.57</b>	<b>3,685.49</b>	<b>15,480.85</b>	<b>12,415.69</b>	<b>17,468.89</b>
<b>4</b>	<b>Tax expenses</b>						
	Current tax:						
	- for the year :	1,117.53	1,605.96	1,024.76	4,070.87	3,565.89	4,966.99
	- tax adjusted for earlier years :	1.28	(64.46)	(51.14)	(63.18)	(348.43)	(6.09)
	Deferred tax (credit)/expense	(32.71)	(71.70)	(17.04)	(155.10)	5.27	(337.57)
	<b>Total tax expenses</b>	<b>1,086.10</b>	<b>1,469.80</b>	<b>956.58</b>	<b>3,852.59</b>	<b>3,222.73</b>	<b>4,623.33</b>
<b>5</b>	<b>Profit for the period / year (3) - (4)</b>	<b>3,147.46</b>	<b>4,669.77</b>	<b>2,728.91</b>	<b>11,628.26</b>	<b>9,192.96</b>	<b>12,845.56</b>
<b>6</b>	<b>Other comprehensive income</b>						
	Items that will not be reclassified subsequently to profit and loss (net of tax)	(72.28)	(148.01)	(73.66)	(261.72)	(220.98)	(165.72)
	Items that will be subsequently reclassified to profit and loss (net of tax)	(102.97)	82.47	33.23	125.98	(455.62)	83.40
	<b>Other comprehensive income for the period / year (net of tax)</b>	<b>(175.25)</b>	<b>(65.54)</b>	<b>(40.43)</b>	<b>(135.74)</b>	<b>(676.60)</b>	<b>(82.32)</b>
<b>7</b>	<b>Total comprehensive income (5) + (6)</b>	<b>2,972.21</b>	<b>4,604.23</b>	<b>2,688.48</b>	<b>11,492.52</b>	<b>8,516.36</b>	<b>12,763.24</b>
<b>8</b>	<b>Profit attributable to:</b>						
	Owners of the Company	3,136.05	4,651.88	2,715.84	11,582.66	9,140.93	12,781.62
	Non-controlling interest	11.41	17.89	13.07	45.60	52.03	63.94
<b>9</b>	<b>Other comprehensive income attributable to:</b>						
	Owners of the Company	(175.16)	(65.16)	(40.26)	(135.45)	(676.30)	(82.46)
	Non-controlling interest	(0.09)	(0.38)	(0.17)	(0.29)	(0.30)	0.14
<b>10</b>	<b>Total comprehensive income attributable to:</b>						
	Owners of the Company	2,960.89	4,586.72	2,675.57	11,447.21	8,464.63	12,699.16
	Non-controlling interest	11.32	17.51	12.91	45.31	51.73	64.08
<b>11</b>	Paid-up equity share capital (face value - Rs. 2 per share)	1,025.35	1,024.83	1,024.45	1,025.35	1,024.45	1,024.54
<b>12</b>	Other equity (including Non-controlling interest)	-	-	-	-	-	1,08,591.01
<b>13</b>	Earnings per share (Face value of Rs. 2 each) basic- (Rs.)*	6.12	9.08	5.30	22.60	17.85	24.95
	Earnings per share (Face value of Rs. 2 each) diluted - (Rs.)*	6.09	9.03	5.28	22.48	17.78	24.87

(\*not annualised for the quarters)

See accompanying note to the unaudited consolidated financial results






## NOTES:

- 1 Metropolis Healthcare Limited (the 'Company' or the 'Parent') and its subsidiaries (referred collectively as the 'Group') are primarily involved in providing pathology and related healthcare services.
- 2 The consolidated financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The consolidated financial results of the Group have been reviewed by the Audit Committee at their meeting held on 04 February 2025 and thereafter approved by the Board of Directors at their meeting held on 04 February 2025. The Statutory Auditors have issued an unmodified review opinion on the unaudited consolidated financial results for the quarter and nine-months period ended 31 December 2024.
- 4 Disclosure of segment-wise information is not applicable, as pathology services is the Group's only business segment.
- 5 In the month of May, June and Nov 2024, the Nomination and Remuneration Committee of the Company approved grant of 65,700, 58,000 and 22,500 Restricted Stock Units (RSU) respectively, pursuant to the Metropolis - Restrictive Stock Unit Plan - 2020 to eligible employees of the Company. This is in addition to the RSU's approved under Restrictive Stock Unit Plan - 2020 to eligible employees of the Company / subsidiaries in the earlier years.
- 6 On 09 December 2024, the Board of Directors of the Company approved acquisition of 100% stake in Core Diagnostics Private Limited, India, from its existing shareholder, Core Diagnostics (Mauritius) Private Limited for a total purchase consideration of Rs. 24,683 lakhs. Following the board approval, the Company has signed share purchase agreement on 09 December 2024. However, pending closure of the conditions precedent, no impact has been given in these results.
- 7 The results of the Group are available for investors at [www.metropolisindia.com](http://www.metropolisindia.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

For Metropolis Healthcare Limited

  
 Amcera Shah  
 Chairperson and Wholtime Director  
 DIN: 00208095  
 Place: Mumbai  
 Date: 04 February 2025



## Annexure A

(pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024)

Name of Key Managerial Personnel and Senior Managerial Personnel	Details			
	Mr. Sameer Patel	Mr. Aditya Shinde	Mr. Alangadan Kannan	Mr. Glen Menezes
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Sameer Patel as Chief Financial Officer and Key Managerial Personnel of the Company.	Relieving Mr. Aditya Shinde as Interim Chief Financial Officer and Key Managerial Personnel of the Company. He will continue to serve as Finance Controller.	Change in designation of Mr. Alangadan Kannan from 'Chief Operating Officer' to 'Chief Business Officer - Region 1'	Elevation of Mr. Glen Menezes from 'Head - Market Operations' to 'National Head - Customer Success'
Date of appointment/ <del>re-appointment</del> /cessation (as applicable) & term of appointment / <del>re-appointment</del>	February 10, 2025  Term of appointment: Full-time employment.	February 09, 2025 (close of business hours)	March 01, 2025 (change in designation)  Term of appointment: Full-time employment.	March 01, 2025  Term of appointment: Full-time employment.
Brief Profile	Mr. Sameer Patel is a qualified Chartered Accountant with over 20 years of post-qualification experience across diverse industries. He commenced his professional journey with Deloitte, where he spent six years in the Statutory Audit department, gaining relevant financial expertise. Subsequently, he transitioned to the retail sector within the Aditya Birla Group, contributing for 5.5 years across well-known brands such as Madhura Garments, Pantaloons, and More Grocery Retail. Most recently, he served for 8.5 years at Restaurant Brands Asia Limited (formerly known as Burger King India Limited) wherein he served in the capacity of Chief Financial Officer during the last two years of his service. Throughout his career, Sameer has demonstrated a strong acumen in financial management, financial planning, and financial compliance.	Not applicable.	Mr. Alangadan Kannan is having a rich experience of 31 years in operations, retail business, customer lifecycle management, customer retention, call center operations, quality control, process design, and re-engineering. He has a proven track record of delivering quality and timely services. His career spans esteemed organizations such as BPL, Airtel and Hicare. He has held key leadership roles, including Chief HR & Operations, Chief Service Operations, and Chief Operating Officer at Metropolis Healthcare Limited. Academically, he holds a B. Com and a PGDBA in Marketing from Symbiosis Center for Distance Learning. He is also a Six Sigma Black Belt certified by the Indian Statistical Institute.	Mr. Glen Menezes is having a rich experience of 16 years in customer experience, service management, and customer relationship design for B2B customer experience & fulfillment. He has been instrumental in designing processes to enhance customer retention. He has held a key leadership role of DGM at Airtel. Academically, he holds an MBA in Operations & Project Management and a Bachelor's Degree in Commerce from Mumbai University.
Disclosure of relationship between directors (in case of appointment of a director)	Not applicable.	Not applicable.	Not applicable.	Not applicable.

